Table 5.

Nephroureterectomy-Free Survival for Patients Undergoing Adjuvant Mitomycin C

Variable	n	Nephroureterectomy	NUxFS rate at 3 years (95% CI)	NUxFS rate at 5 years (95% CI)
Overall	28	5	0.76 (0.60, 0.97)	0.76 (0.60, 0.97)
Tumor grade
Low	21	3	0.82 (0.65, 1)	0.82 (0.65, 1)
High	7	2	0.67 (0.38, 1)
Focality
Solitary	9	3	0.8 (0.62, 1)	0.8 (0.62, 1)
Multifocal	9	2	0.71 (0.45, 1)	0.71 (0.45, 1)
Renal function at diagnosis
eGFR ≥60	15	3	0.76 (0.55, 1)	0.76 (0.55, 1)
eGFR <60	13	2	0.79 (0.56, 1)	0.79 (0.56, 1)
Treatment indication
Elective	13	2
Imperative	13	3	0.7 (0.47, 1)	0.7 (0.467, 1)
Palliative	2	0	1 (1, 1)	1 (1, 1)
Tobacco history
Nonsmoker	12	3	0.7 (0.47, 1)
Smoker	16	2	0.82 (0.61, 1)	0.82 (0.61, 1)
Delivery method
Ureteral catheter	19	4	0.86 (0.69, 1)	0.56 (0.32, 0.1)
Nephrostomy tube	9	1	0.63 (0.37, 1)	0.833 (0.58,1)
Lynch syndrome
Negative	23	4	0.72 (0.52, 1)	0.56 (0.32, 1)
Positive	5	1	0.86 (0.63,1)	0.67 (0.41, 1)

NUxFS = nephroureterectomy-free survival.